

DAFTAR PUSTAKA

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I BF. Ovarian cancer incidence and mortality. International Agency for Research on Cancer (IARC) Globocan. 2020. p. 5–6.
2. Reid BM, Permuth JB ST. Epidemiology of ovarian cancer: a review. *Cancer Biol Med.* 2017;14(1):9–32.
3. American Cancer Society. Cancer facts and figures 2018. American Cancer Society. 2018.
4. Torre L, Trabert B, DeSantis C. Ovarian cancer statistics, 2018. *CA Cancer J Clin.* 2018;68(4):284–96.
5. Globocan. Cancer incident in Indonesia. Vol. 858, International Agency for Research on Cancer. 2020. p. 1–2.
6. Trihandini I, Nurrika D. Analisis ketahanan hidup penderita kanker ovarium epithelial di RS Dharmais Jakarta. *J Kesehat Masy Nas.* 2010;5(3):139–44.
7. Jones PM, Drapkin R. Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms. *Front Oncol.* 2013;3(217):1–10.
8. Rambe IR, Asri A, Adrial A. Profil tumor ganas ovarium di laboratorium patologi anatomi fakultas kedokteran universitas andalas periode Januari 2011 sampai Desember 2012. *J Kesehat Andalas.* 2014;3(1):54–7.
9. Salazar C, Campbell IG, Gorringer KL. When is “type I” ovarian cancer not “type I”? indications of an out-dated dichotomy. *Front Oncol.* 2018;8(December):1–9.
10. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. *Int J Mol Sci.* 2019;20(4).
11. ADISASMITA A, MARYANI D, DWIPOYONO B. Hubungan antara Menyusui dengan Risiko Kanker Ovarium. *Indones J Cancer.* 2016;10(3):93.
12. Simamora RPA, Hanriko R, Sari RDP. Hubungan usia , jumlah paritas , dan usia menarche terhadap derajat histopatologi kanker ovarium di RSUD Dr . H . Abdul Moeloek Bandar Lampung tahun 2015-2016. *Majority.* 2018;7(2):7–13.
13. Nurlailiyani. Hubungan antara usia pasien dengan derajat keganasan Tumor ovarium primer di RSUD DR. Moewardi tahun 2011-2012. Institutional Repository UNS. 2013.

14. Dunneram Y, Greenwood DC, Cade JE. Diet, menopause and the risk of ovarian, endometrial and breast cancer. *Proc Nutr Soc.* 2019;78(3):438–48.
15. Yanti DAM, Sulistianingsih A. Faktor-faktor determinat terjadinya kanker ovarium di RSUD Abdoel Mpelok Provinsi Lampung tahun 2015. *J Keperawat.* 2016;7(2):79–87.
16. Garbar V, Newton BW. *Anatomy, abdomen and pelvis , gallbladder blood supply and lymphatics.* StatPearls Publishing. 2020. p. 1–4.
17. Snell RS. *Clinical anatomy by systems.* Suwahjo A, Antoni Y, editors. Jakarta: Penerbit Buku Kedokteran ECG; 2012. 809–811 p.
18. Mescher AL. *Junqueira’s basic histology: text & atlas.* 12th ed. Hartanto H, editor. Jakarta: Penerbit Buku Kedokteran ECG; 2012.
19. Gordon BL. *A Textbook of histology.* 3rd ed. Elsevier. Philadelphia; 2007. 637 p.
20. Ariningtyas N. CA 125 dan pemakaian Klinis dalam penatalaksanaan kanker ovarium. *Qanun Med - Med J Fac Med Muhammadiyah Surabaya.* 2018;2(2):73–82.
21. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Health.* 2019;11:287–99.
22. Gaona-Luviano P, Medina-Gaona L, Magaña-Pérez K. Epidemiology of ovarian cancer. *Chinese Clin Oncol.* 2020;9(4):2.
23. Fadillah A, Friadi A. Metastasis of residive mucinous ovarian carcinoma to umbilicus, peritoneum, and ascites fluid with no malignancy marker found in the previous post-operative histopathological examination. *Andalas Obstet Gynecol J.* 2019;3(2):25127.
24. Chornokur G, Amankwah EK, Schildkraut JM PC. Global ovarian cancer health disparities. *Gynecol Oncol.* 2013;129(1):258–264.
25. Mohammadian M, Ghafari M, Khosravi B. Variations in the incidence and mortality of ovarian cancer and their relationship with the human development index in European Countries in 2012. *Biomed Res Ther.* 2017;4(8):1541–1557.
26. Poole E, Merritt M, Jordan S. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. *Cancer Epidemiol Prev Biomark.* 2013;22(3):431.
27. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: pathogenesis and current recommendations for prophylactic surgery. *J Turkish-German Gynecol Assoc.* 2019;20(1):47–54.
28. Penny S. Ovarian cancer overview. *Radiol Technol.* 2020;91(6).

29. Wijaya I. Hubungan kadar CA 125, HEA dan indeks morfologi usg dengan kanker ovarium tipe epitelial masa premenopause. Univ Udayana. 2017;
30. Katabuchi H. *Comprehensive gynecology and obstetrics frontiers in ovarian cancer science*. Springer. 2017. 37 p.
31. Toss A, Tomasello C, Razzaboni E. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. *Biomed Res Int*. 2015;2015(1):11.
32. Nakamura K, Banno K, Yanokura M. Features of ovarian cancer in Lynch syndrome. *Mol Clin Oncol*. 2014;2(6):909–16.
33. McCann SE, Freudenheim JL, Marshall JR, Graham S. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. *J Nutr*. 2003;133(6):1937–42.
34. Ong JS, Cuellar-Partida G, Lu Y, Fasching PA, Hein A, Burghaus S, et al. Association of vitamin D levels and risk of ovarian cancer: a mendelian randomization study. *Int J Epidemiol*. 2016;45(5):1619–30.
35. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. *Am J Surg Pathol*. 2010;34(3):433–43.
36. Erickson BK, Conner MG LCJ. The role of fallopian tube in the origin of ovarian cancer. *Am J Obs Gynecol*. 2013;209.
37. Koshiyama M, Matsumura N KI. Recent concepts of ovarian carcinogenesis: type I and type II. *Biomed Res Int* 2014. 2014;2014(1):2–4.
38. Kumar V, Abbas A, Aster J. Sistem genitalia wanita dan payudara. In: Ham M, Saraswati M, editors. *Buku Ajar Patologi Robbins*. 10th ed. Elsevier; 2015. p. 696–7.
39. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN, et al. Pathology and classification of ovarian tumors. *Cancer*. 2003;97(10 SUPPL.):2631–42.
40. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *Lancet*. 2019;393(10177):1240–53.
41. Nucci M, Parra-Herran C. Epithelial neoplasms of the ovary. In: Stolnicu S, Fehmi R, editors. *Gynecologic Pathology*. Elsevier; 2021. p. 577–639.
42. Arania R, Windarti I. Karakteristik pasien kanker ovarium di RSUD Dr . H . Abdul Moeloek Lampung periode 2009-2013. *J Kedokt Unila*. 2015;5:43–7.
43. Budiana I. Tumor ovarium prediksi keganasan prabedah. *Medicina (B Aires)*. 2017;44(23):182.
44. Rahmawati H, ER D, Pakasi RD. Kanker ovarium disgerminoma. *Indones J Clin Pathol Med Lab*. 2016;19(1):51.

45. Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. *Hematol Oncol Clin North Am.* 2018;32(6):943–64.
46. Nash Z, Menon U. Ovarian cancer screening: current status and future directions. *Clin Obstet Gynaecol.* 2020;65:32–45.
47. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynecol Obstet.* 2014;124(1):1–5.
48. Larsson S, Eoli M, Finocchiaro G. Epithelial ovarian cancer/fallopian tube cancer/ primary peritoneal cancer & less common Histopathologies. *encycl cancer.* *Encycl Cancer.* 2016;2671–4.
49. Malik YA, Friadi A. Perbandingan akurasi skor ROMA dan IOTA dalam prediksi keganasan tumor ovarium. *J Obgin Emas.* 2020;4(1):70–6.
50. Ramadhan A. Kategori umur menurut Depkes RI. Departemen Kesehatan RI. 2014.
51. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. GPE discussion paper series: No31. Geneva: World Health Organization. 2015.
52. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394–424.
53. Nofia D. Analisis faktor yang berhubungan dengan kejadian kanker ovarium tipe epitel di RSUP Dr. M. Djamil Padang tahun 2017-2018. *eSkripsi Univ Andalas.* 2020;
54. Merrit MA, Pari MD, Vitonis AF, Titus LJ, Cramer DW and TK. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. *Hum Reprod.* 2013;28(5):1406–17.
55. Johari B. Insidensi kanker ovarium berdasarkan faktor risiko di RSUP Haji Adam Malik tahun 2008-2011. *e-jurnal Fak Kedokt USU.* 2013;1(1).
56. Lannywati G. Seluk beluk menopause. *Media Penelit dan Pengemb Kesehat.* 2009;19(4):193–7.
57. Dahlan M. Besar sampel dan cara pengambilan sampel. 3rd ed. Jakarta: Salemba Medika; 2010. 46 p.
58. Nababan EHF, Sihotang J, Sasputra IN, Damanik EMB. Faktor Risiko Kanker Ovarium Jenis Epitelial Di RSUD Prof. Dr.W.Z Johannes Kota Kupang Nusa Tenggara Timur Tahun 2016-2019. *Cendana Med J.* 2021;9(2):200.
59. Olsen CM, Green AC, Nagle CM, Jordan SJ, Whiteman DC, Bain CJ, et al. Epithelial ovarian cancer: Testing the “androgens hypothesis.” *Endocr*

Relat Cancer. 2008;15(4):1061–8.

60. Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, et al. Differences In Presentation and Survival of Asians Compared to Caucasians with Ovarian Cancer: An NRG Oncology/GOG Ancillary Study of 7914 Patientes. 2020;154(2):420–5.
61. Merritt MA, De Pari M, Vitonis AF, Titus LJ, Cramer DW, Terry KL. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Hum Reprod. 2013;28(5):1406–17.
62. Ardiansyah A. Dasar dasar Onkologi. Surabaya: Airlangga University Press; 2017. 37 p.
63. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.
64. McSorley M, Alberg A, Allen D, Allen N, Brinton L, Dorgan J, et al. Pre-diagnostic circulating follicle stimulating hormone (FSH) concentrations. Bone. 2009;23(1):1–7.

